Teng J. Fang

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College
Tianjin, 300020, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

Journal: Blood cancer journal

Published: April 09, 2026

Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.

Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.

Journal: Blood

Published: March 26, 2025

Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.

Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.

Journal: Blood

Published: March 26, 2025

Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.

Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.

Journal: Blood advances

Published: January 21, 2025

A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28.

A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28.

Journal: Biomarker research

Published: December 12, 2024

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

Journal: Frontiers in immunology

Published: July 25, 2024

Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment.

Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment.

Journal: Haematologica

Published: February 26, 2024

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.

Journal: Haematologica

Published: January 20, 2024

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

Journal: Blood cancer journal

Published: November 22, 2023

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.

Journal: EBioMedicine

Published: August 01, 2023

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma.

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma.

Journal: Blood science (Baltimore, Md.)

Published: December 14, 2022

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.

Journal: Journal of translational medicine

Published: October 02, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026